Page 347 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 24 Complement and Immunoglobulin Biology Leading to Clinical Translation 284.e5

191. Moskowitz C, Ribrag V, Michot J, et al Blockade with the monoclonal 213. Hillmen P, Young NS, Schubert J, et al: The complement inhibitor
antibody pembrolizumab (MK-3475) in patients with classical Hodgkin eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med
lymphoma after brentuximab vedotin failure: Preliminary results from a 355:1233–1243, 2006.
phase 1b study (KEYNOTE-013). ASH Annual Meeting. 2014. 214. Brodsky RA, Young NS, Antonioli E, et al: Multicenter phase 3 study
192. Why is it so difficult to use gemtuzumab ozogamicin? Blood of the complement inhibitor eculizumab for the treatment of patients
121(24):4813–4814, 2013. with paroxysmal nocturnal hemoglobinuria. Blood 111(4):1840–1847,
193. Castaigne S, Pautas C, Terre C, et al: Effect of gemtuzumab ozogamicin 2008.
on survival of adult patients with de-novo acute myeloid leukaemia 215. Hillmen P, Muus P, Duhrsen U, et al: Effect of the complement
(ALFA-0701): A randomised, open-label, phase 3 study. Lancet inhibitor eculizumab on thromboembolism in patients with paroxysmal
379(9825):1508–1516, 2012. nocturnal hemoglobinuria. Blood 110(12):4123–4128, 2007.
194. Petersdorf SH, Kopecky KJ, Slovak M, et al: A phase 3 study of 216. Araten DJ, Thaler HT, Luzzatto L: High incidence of thrombosis
gemtuzumab ozogamicin during induction and postconsolidation in African-American and Latin-American patients with paroxys-
therapy in younger patients with acute myeloid leukemia. Blood mal nocturnal haemoglobinuria. Thromb Haemost 93(1):88–91,
121(24):4854–4860, 2013. 2005.
195. Morris EC, Rebello P, Thomson KJ, et al: Pharmacokinetics of alem- 217. Kelly R, Hill A, Arnold LM, et al: Long-term treatment with eculi-
tuzumab used for in vivo and in vitro T-cell depletion in allogeneic zumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and
transplantations: relevance for early adoptive immunotherapy and improved survival. Blood 117:6786, 2011.
infectious complications. Blood 102(1):404–406, 2003. 218. Kelly R, Arnold L, Richards S, et al: The management of pregnancy in
196. MacGlashan DW, Jr, Bochner BS, Adelman DC, et al: Down- paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J
regulation of Fc(epsilon)RI expression on human basophils during in Haematol 149:446–450, 2010.
vivo treatment of atopic patients with anti-IgE antibody. J Immunol 219. Dmytrijuk A, Robie-Suh K, Coehn M, et al: FDA report: Eculizumab
158(3):1438–1445, 1997. (Soliris (R)) for the treatment of patients with paroxysmal nocturnal
197. Mankarious S, Lee M, Fischer S, et al: The half-lives of IgG subclasses hemoglobinuria. Oncologist 13:993–1000, 2008.
and specific antibodies in patients with primary immunodeficiency who 220. Nishimura J, Yamamoto M, Hayashi S, et al: Genetic variants in C5
are receiving intravenously administered immunoglobulin. J Lab Clin and poor response to eculizumab. N Engl J Med 370(7):632–639, 2014.
Med 112:634–640, 1988. 221. Brodbeck WG, Kuttner-Kondo L, Mold C, et al: Structure/function
198. WHO: INN Working Document, 2009, World Health Organization. studies of human decay-accelerating factor. Immunology 101(1):104–
9.251. 111, 2000.
199. Mc Lean RH, Walsh TR: Chapter 8 complement, Handbook of Human 222. Holguin MH, Martin CB, Bernshaw NJ, et al: Analysis of the effects
Immunology, Lefell et al. Eds, CRC Press, 1997, p 236. of activation of the alternative pathway of complement on erythrocytes
200. Pfarr N, Prawitt D, Kirschfink M, et al: Linking C5 deficiency to an with an isolated deficiency of decay accelerating factor. J Immunol
exonic splicing enhancer mutation. J Immunol 174:4175–4177, 2005. 148(2):498–502, 1992.
201. Wang X: Inherited Human Complement C5 deficiency nonsense 223. Rondelli T, et al: Polymorphism of the complement receptor 1 gene
mutations in exons 1 (Gln’ to Stop) and 36 (Arg1458t o Stop) and com- correlates with the hematologic response to eculizumab in patients with
pound heterozygosity in three African-American families. J Immunol paroxysmal nocturnal hemoglobinuria. Haematologica 99:262–266,
154:5464–5471, 1995. 2014. doi: 10.3324/haematol.2013.090001.
202. Evans M, Rollins S, Wolff D, et al: In vitro and in vivo inhibition of 224. Zuber J, Fakhouri F, Roumenina LT, et al: Use of eculizumab for
complement activity by a single chain Fv fragment recognizing human atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat
C5. Mol Immunol 32:1183–1195, 1995. Rev Nephrol 8(11):643–657, 2012.
203. Matis L, Rollins S: Complement specific antibodies: designing novel 225. El-Husseini A, Hannan S, Awad A, et al: Thrombotic microangiopathy
anti-inflammatories. Nat Med 8:839–842, 1995. in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney
204. Thomas T, Rollins S, Rother R, et al: Inhibition of complement activity Dis 65(1):127–130, 2015.
by humanized anti C5 antibody and single chain Fv. Mol Immunol 226. Legendre CM, Licht C, Muus P, et al: Terminal complement inhibitor
33:1389–1401, 1996. eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med
205. Mueller J, Giannoni M, Hartman S, et al: Humanized porcine VCAM- 368(23):2169–2181, 2013.
specific monoclonal antibodies with chimeric IgG2/G4 constant 227. Ardissino G, Testa S, Possenti I, et al: Discontinuation of eculizumab
regions block human leukocyte binding to porcine endothelial cells. maintenance treatment for atypical hemolytic uremic syndrome: a
Mol Immunol 34:441–452, 1997. report of 10 cases. Am J Kidney Dis 64(4):633–637, 2014.
206. Hill A, Hillmen P, Richards SJ, et al: Sustained response and long-term 228. Shapira I, Andrade D, Allen SL, et al: Brief report: induction of sus-
safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood tained remission in recurrent catastrophic antiphospholipid syndrome
106(7):2559–2565, 2005. via inhibition of terminal complement with eculizumab. Arthritis
207. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al: Assessing Rheum 64(8):2719–2723, 2012.
complement blockade in patients with paroxysmal nocturnal hemoglo- 229. Roth A, Huttmann A, Rother RP, et al: Long-term efficacy of the
binuria receiving eculizumab. Blood 125:775–783, 2015. complement inhibitor eculizumab in cold agglutinin disease. Blood
208. Rother R, Mojcik C, McCroskery E: Inhibition of terminal comple- 113(16):3885–3886, 2009.
ment: a novel therapeutic approach for the treatment of systemic lupus 230. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al: Eculizumab in
erythematosus. Lupus 13:328–334, 2004. severe Shiga-toxin-associated HUS. N Engl J Med 364(26):2561–2563,
209. Verrier ED, Shernan SK, Taylor KM, et al: Terminal complement 2011.
blockade with pexelizumab during coronary artery bypass graft 231. Barnett AN, Asgari E, Chowdhury P, et al: The use of eculizumab in
surgery requiring cardiopulmonary bypass: a randomized trial. JAMA renal transplantation. Clin Transplant 27(3):E216–E229, 2013.
291(19):2319–2327, 2004. 232. Broome C, McCloskey J, Girlanda R. successful management of calci-
210. Armstrong P, Granger C, Adams P, et al: Pexelizumab for acute neurin induced thrombotic microangiopathy (TMA) with eculizumab after
ST-elevation myocardial infarction in patients undergoing primary non-renal solid organ transplantation. ASH Annual Meeting. 2013. 122.
percutaneous coronary intervention: a randomized controlled trial. 233. Pittock SJ, Lennon VA, McKeon A, et al: Eculizumab in AQP4-IgG-
JAMA 297:43–51, 2007. positive relapsing neuromyelitis optica spectrum disorders: an open-
211. Appel G, Waldman M, Radhakrishnan J: New approaches to the treat- label pilot study. Lancet Neurol 12(6):554–562, 2013.
ment of glomerular diseases. Kidney Int 70:s45–s50, 2006. 234. Howard JF, Jr, Barohn RJ, Cutter GR, et al: A randomized, double-
212. Hillmen P, Hall C, Marsh J, et al: effect of eculizumab on hemolysis blind, placebo-controlled phase II study of eculizumab in patients with
and transfusion requirements in patients with paroxysmal nocturnal refractory generalized myasthenia gravis. Muscle Nerve 48(1):76–84,
hemoglobinuria. N Engl J Med 350:552–559, 2004. 2013.